Aishun Jin
aishunjin@cqmu.edu.cn
Chinese, Japanese, English
Chongqing
Chongqing Medical University
Basic Medical Sciences
  • 1983-1988 Bachelor: Harbin Medical University, Preventive Medicine
  • 2000-2002 Master: University of Tokyo, Department of Immunoregulation
  • 2002-2006 Doctorate: Tokyo Medical and Dental University, Molecular Oncology
  • Led 5 National Natural Science Foundation projects
  • Published in international journals like NM, NC, NBE, STTT, Cell Reports
  • Received 1 international invention patent and 20 national invention patents
  • 1988-1999 - Heilongjiang CDC - Chief Physician
  • 1999-2000 - Kyoto University - Special Researcher
  • 2006-2010 - University of Toyama - Postdoctoral Researcher
  • 2008-2009 - SC.World.Inc. - Researcher
  • 2010-2017 - Harbin Medical University - Professor
  • 2011-2013 - University of Toyama - Researcher
  • 2017-present - Chongqing Medical University - Professor
  • 2021: Top 10 Chongqing Science and Technology Innovation Annual Figures
  • 2021: Outstanding Communist Party Member of Chongqing
  • 2020: Chongqing Model Teacher
  • 2019: Chongqing Talent Plan Innovation and Entrepreneurship Leading Talent
  • 2019: Chongqing Academic and Technical Leader
  • 2017: Bayu Scholar Distinguished Professor
Tumor Immunology and Immunotherapy
  • Rapid cloning of antigen-specific T-cell receptors by leveraging the cis activation of T cells., Eiji Kobayashi, Aishun Jin, Hiroshi Hamana, Kiyomi Shitaoka, Kazuto Tajiri, Seisuke Kusano, Shigeyuki Yokoyama, Tatsuhiko Ozawa, Tsutomu Obata, Atsushi Muraguchi, Hiroyuki Kishi, 2022
  • A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood., Aishun Jin, Tatsuhiko Ozawa, Kazuto Tajiri, Tsutomu Obata, Sachiko Kondo, Koshi Kinoshita, Shinichi Kadowaki, Kazuo Takahashi, Toshiro Sugiyama, Hiroyuki Kishi, Atsushi Muraguchi, 2009
  • Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants., Tingting Li, Xiaojian Han, Chenjian Gu, Hangtian Guo, Huajun Zhang, Yingming Wang, Chao Hu, Kai Wang, Fengjiang Liu, Feiyang Luo, Yanan Zhang, Jie Hu, Wang Wang, Shenglong Li, Yanan Hao, Meiying Shen, Jingjing Huang, Yingyi Long, Shuyi Song, Ruixin Wu, Song Mu, Qian Chen, Youhua Xie, Haitao Yang, Bo Zhang, Ailong Huang, Aishun Jin, 2021
  • Rapid isolation of antigen-specific antibody-secreting cells using a chip-based immunospot array., Aishun Jin, Tatsuhiko Ozawa, Kazuto Tajiri, Tsutomu Obata, Hiroyuki Kishi, Atsushi Muraguchi, 2011
  • Structures of Omicron Spike complexes and implications for neutralizing antibody development., Hangtian Guo, Yan Gao, Tinghan Li, Tingting Li, Yuchi Lu, Le Zheng, Yue Liu, Tingting Yang, Feiyang Luo, Shuyi Song, Wei Wang, Xiuna Yang, Henry C Nguyen, Hongkai Zhang, Ailong Huang, Aishun Jin, Haitao Yang, Zihe Rao, Xiaoyun Ji, 2022
  • A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2., Xiaojian Han, Yingming Wang, Shenglong Li, Chao Hu, Tingting Li, Chenjian Gu, Kai Wang, Meiying Shen, Jianwei Wang, Jie Hu, Ruixin Wu, Song Mu, Fang Gong, Qian Chen, Fengxia Gao, Jingjing Huang, Yingyi Long, Feiyang Luo, Shuyi Song, Shunhua Long, Yanan Hao, Luo Li, Yang Wu, Wei Xu, Xia Cai, Qingzhu Gao, Guiji Zhang, Changlong He, Kun Deng, Li Du, Yaru Nai, Wang Wang, Youhua Xie, Di Qu, Ailong Huang, Ni Tang, Aishun Jin, 2021
  • Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants., Chao Hu, Meiying Shen, Xiaojian Han, Qian Chen, Luo Li, Siyin Chen, Jing Zhang, Fengxia Gao, Wang Wang, Yingming Wang, Tingting Li, Shenglong Li, Jingjing Huang, Jianwei Wang, Ju Zhu, Dan Chen, Qingchen Wu, Kun Tao, Da Pang, Aishun Jin, 2022
  • International Invention Patent; Cell Screening Method (JP-4148367 PCT/JP2008063874); Inventors: Aishun Jin, Hiroyuki Kishi, Atsushi Muraguchi, Aishun Jin, Hiroyuki Kishi, Atsushi Muraguchi
Tumor Immunology Immunotherapy T-Cells Antigen Cancer Therapeutics Molecular Oncology Research

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.